


Figure S7. Gene expression profiling of melanoma cells treated with AZD6244+BEZ235+TRAIL indicates significant increase of biological functions related to cell death. (a), Edwards-VENN diagram analysis of significantly modulated genes (upper panel, upregulated genes; lower panel, downregulated genes) in Me13 cells treated with AZD6244 (red rectangle), or BEZ235 (blue rectangle) or AZD6244+TRAIL (fuchsia shape), TRAIL (green cogwheel) or the AZD6244+BEZ235+TRAIL association (light blue circle). **(b)**, Downstream effect analysis (by IPA) based on the two subsets of genes identified by the light blue circles in panel **a**. See Table **S3** for the list of genes. Only biological functions with significant z score statistic (>2 , indicating increase of biological function, or <-2 , indicating decrease of biological function) and significant overlap p value are shown.

a



b




Figure S8. Gene expression profiling of melanoma cells treated with AZD6244, TRAIL and their combination. (a), Edwards-VENN diagram analysis of significantly modulated genes (upper panel, upregulated genes; lower panel, downregulated genes) in ME13 cells treated with AZD6244 (red rectangle), or TRAIL (blue rectangle) or AZD6244+TRAIL (fuchsia shape). **(b)**, Downstream effect analysis (by IPA) based on the two subsets of genes identified by the fuchsia shape in panel **a**. Only biological functions with significant Z score statistic (>2 , indicating increase of biological function, or <-2 , indicating decrease of biological function) and significant overlap P value are shown. See **Table S4** for the list of genes mentioned in panel B.




Figure S9. Enhanced melanoma apoptosis by association of mTRAIL with AZD6244 and BEZ235. Melanoma cells (Me1), stained with CFSE as described in ref. 25, were treated with AZD6244 (0.05 mM), BEZ235 (0.05 mM) or both inhibitors, and then co-cultured with CD34⁺ cells transduced with an adenoviral vector encoding human TRAIL (mTRAIL, ref. 27). Extent of melanoma apoptosis was assessed at 72 h by staining for annexin-V and Propidium iodide (PI) after gating on CFSE⁺ melanoma cells. Numbers in each dotplot indicate % of cells in each of the four quadrants.




Figure S10. Enhanced melanoma apoptosis by association of TRAIL with PD0325901 and rapamycin. Me13 cells were treated with TRAIL (10 ng/mL), PD0325901 (5 nM), rapamycin (10 nM) or their combinations. Apoptosis was assessed at 72 h by flow cytometry. Apoptosis induced by the PD0325901/rapamycin/TRAIL and PD0325901/TRAIL combinations was significantly higher compared to the effects of single agents and of the PD0325901/rapamycin and rapamycin/TRAIL associations. Mean values (\pm S.D.) for three independent experiments ($p < 0.001$ for all comparisons, by ANOVA and SNK test).




Figure S11. The association of AZD6244 and TRAIL promotes caspase-dependent melanoma apoptosis. Melanoma cell lines Me5 and Me75 were treated with AZD6244 (0.05 μ M), or TRAIL (25 ng/mL) or their combinations for 72 h, in the presence of the pancaspase inhibitor z-VAD-fmk or of the negative control peptide z-FA-fmk, and apoptosis was assessed by Annexin-V/PI assay. Results shown as sum of early (annexin-V⁺ PI⁻) and late (annexin-V⁺ PI⁺) apoptosis values. Mean values (\pm S.D.) for three independent experiments. Statistical analysis by ANOVA followed by SNK test. ***: p<0.001, **: p<0.01.




Figure S12. Modulation of Mcl-1 in melanoma cells treated with TRAIL, AZD6244, BEZ235 and their combinations. Modulation of MCL-1 expression by AZD6244, BEZ235, TRAIL and their combination assessed in two melanoma cell lines (Me 13 and Me 41) by Western Blot analysis at 48h of treatment.